Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

[1]  D. Breen,et al.  Indwelling pleural catheters for malignant pleural effusion. , 2015, International journal of palliative nursing.

[2]  Y. C. Lee,et al.  Advantages of indwelling pleural catheters for management of malignant pleural effusions , 2013, Current Respiratory Care Reports.

[3]  Yasushi Totoki,et al.  KIF5B-RET fusions in lung adenocarcinoma , 2012, Nature Medicine.

[4]  Yan Sun,et al.  Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. , 2010, The Lancet. Oncology.

[5]  Edward S. Kim,et al.  Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  N. Saijo,et al.  Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. , 2007, Lung cancer.

[7]  R. Morice,et al.  Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer. , 2007, Chest.

[8]  A. Tremblay,et al.  Use of tunnelled catheters for malignant pleural effusions in patients fit for pleurodesis , 2007, European Respiratory Journal.

[9]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[10]  R. Herbst,et al.  Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade , 2007, Molecular Cancer Therapeutics.

[11]  A. Tremblay,et al.  Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. , 2005, Chest.

[12]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[13]  N. Saijo,et al.  Small In-Frame Deletion in the Epidermal Growth Factor Receptor as a Target for ZD6474 , 2004, Cancer Research.

[14]  G. Fontanini,et al.  Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Mackey,et al.  A randomized, phase III, double-blind, placebo-controlled trial of intrapleural instillation of methylprednisolone acetate in the management of malignant pleural effusion. , 2003, Chest.

[16]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  B. Curry,et al.  ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. , 2002, Cancer research.

[18]  L. Ellis,et al.  Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. , 2000, The American journal of pathology.

[19]  E. Smit,et al.  Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. , 2000, The oncologist.

[20]  C. Bucana,et al.  Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  J. Roth,et al.  Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter. , 2000, The Annals of thoracic surgery.

[23]  K. Kovitz,et al.  A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions , 1999, Cancer.

[24]  D. Hicklin,et al.  Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  R. Light,et al.  Vascular endothelial growth factor in pleural fluid. , 1999, Chest.

[26]  D. Thickett,et al.  Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions , 1999, Thorax.

[27]  S. Sone,et al.  Interleukin-1 receptor antagonist in pleural effusion due to inflammatory and malignant lung disease. , 1996, The European respiratory journal.

[28]  F. Rodríguez‐Panadero,et al.  Survival and talc pleurodesis in metastatic pleural carcinoma, revisited. Report of 125 cases. , 1993, Chest.

[29]  R. Whyte,et al.  The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma. , 1993, The American journal of pathology.

[30]  W. Arend.  Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. , 1991, The Journal of clinical investigation.

[31]  A. Tsao.  Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR) , 2012 .

[32]  A. Ryan,et al.  ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. , 2006, Oncology research.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  H. Colt,et al.  Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. , 2000, Chest.